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Abstract
In the absence of a parenteral drug, oral oseltamivir is currently recommended by the WHO for treating H5N1 influenza.
Whether oseltamivir absorption is adequate in severe influenza is unknown. We measured the steady state, plasma
concentrations of nasogastrically administered oseltamivir 150 mg bid and its active metabolite, oseltamivir carboxylate
(OC), in three, mechanically ventilated patients with severe H5N1 (male, 30 yrs; pregnant female, 22 yrs) and severe H3N2
(female, 76 yrs). Treatments were started 6, 7 and 8 days after illness onset, respectively. Both females were sampled while
on continuous venovenous haemofiltration. Admission and follow up specimens (trachea, nose, throat, rectum, blood) were
tested for RNA viral load by reverse transcriptase PCR. In vitro virus susceptibility to OC was measured by a neuraminidase
inhibition assay. Admission creatinine clearances were 66 (male, H5N1), 82 (female, H5N1) and 6 (H3N2) ml/min.
Corresponding AUC0–12 values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml)
were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC50 (0.69 ng/ml)
isolated from the H5N1 infected female. Two patients with follow-up respiratory specimens cleared their viruses after 5
(H5N1 male) and 5 (H3N2 female) days of oseltamivir. Both female patients died of respiratory failure; the male survived.
150 mg bid of oseltamivir was well absorbed and converted extensively to OC. Virus was cleared in two patients but two
patients died, suggesting viral efficacy but poor clinical efficacy.
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Introduction
The number of anti influenza drugs is currently limited to oral
amantadine, rimantadine, oseltamivir and inhaled zanamivir and
there are no registered parenteral formulations. The need for
effective anti influenza drugs has been heightened by the
emergence of highly pathogenic, H5N1 influenza A infection that
characteristically causes a severe, rapidly progressive pneumonitis
with a mortality rate of between 60 to 80%.[1,2,3,4,5] Fear of a
possible H5N1 pandemic has prompted many countries to
stockpile oseltamivir.
Oseltamivir phosphate (OP) is licensed for the prophylaxis and
treatment of uncomplicated human influenza A and B. The active
metabolite, oseltamivir carboxylate (OC), inhibits the influenza
virus neuraminidase from destroying host cell sialic acid receptors,
thereby preventing the release and spread of newly formed virions
from epithelial cell surfaces.[6] Early use (#48 h) oseltamivir
reduces illness duration and secondary bacterial infections in
influenza A and B infected adults and children.[7]
The World Health Organisation (WHO) recommends standard
dose (75 mg bid in adults) oseltamivir as first line treatment against
H5N1 infection with advice that clinicians consider 150 mg for
severely ill patients with pneumonitis. Observational data suggest
oral oseltamivir is better than no treatment and that surviving
H5N1 is more likely if given early.[2,8] However, there have been
no prospective studies, no published pharmacokinetic (PK) data in
H5N1 infected patients and mortality remains high in oseltamivir
treated H5N1 patients.
Oseltamivir, up to 500 mg bd, is well tolerated; the main side
effects have been limited to headache, nausea and mild
vomiting.[9] Mean steady state ($48 h) trough OC concentrations
(Cmin) in mild influenza patients and healthy subjects are ,200
and ,300 ng/ml with 75 and 150 mg bid, respectively; the
corresponding mean AUC0–12 values are 2270 and 4900 ng.h/
ml.[9,10,11,12] OC is filtered and secreted into the urine via the
human organic anion transporter 1; doses should be halved in
patients with a creatinine clearance (CCRCl) of ,30 ml/minute.
The half life ranges from 6 to 10 hours in normal individuals and
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renal failure.[13] There are recent dose recommendations (Roche
Product Information Sheet, 2007) for patients on chronic
haemodialysis and chronic ambulatory peritoneal dialysis (CAPD).
PK data are lacking in patients on continuous venovenous
heamofiltration (CVVH) but it has been shown in vitro that OC
crosses the haemofilter freely and has a sieving coefficient (Sieving
coefficient=OC concentration in the ultrafiltrate/mean OC
concentration of the haemofilter arterial and venous limbs) of 1,
consistent with its polar nature and low protein binding (,3%);
therefore, the CVVH ultrafiltration rate approximates to the
glomerular filtration rate (GFR).[14]
The PK PD (pharmacodynamic) relationships in H5N1 are
unknown. In vitro,m e a nI C 50 OC values against H5N1 vary by viral
clade and methodology, ranging from ,0.5 (0.14 ng/ml) to
11.45 nmol/ml (3.19 ng/ml) for clades 2 and 3 and 0.09 (0.03) to
2.3 (0.8) nmol/ml (ng/ml) for clade 1.[15,16] These values are many
fold lower than OC plasma concentrations in mild influenza but the
clinical efficacy of oseltamivir alone in H5N1 is limited.[1,2,3]
Reasons for this may include irreversible lung damage at presenta-
tion, immune mediated pathology, development of H5N1 resistance
to OC, reduced OC tissue distribution/penetration and low
oseltamivir absorption in severely ill patients secondary to possible
gastric paresis, small bowel ileus or diarrhoea.[5,17] Better insight
into the pharmacokinetics and pharmacodynamics of OC in patients
with H5N1 and other forms of severe influenza is urgently needed.
Herein, we report the PK of nasogastrically administered
oseltamivir 150 mg bid in three severely ill patients with H5N1
(n=2) and H3N2 influenza who were also treated with CVVH.
Methods
The patients, a 30 years old male (A), and a 22 years old, 7
months pregnant female (B) with H5N1 influenza and one 76
years old female (C) with H3N2 influenza, were admitted to the
intensive care unit (ICU) of the Bach Mai hospital, Hanoi,
Vietnam. Written informed consent was obtained from patients or
their relatives. The study was approved retrospectively by the Bach
Mai hospital Ethics Committee because of the importance of
studying rapidly such patients in the absence of a prospectively
approved protocol.
Virological diagnosis and viral load measurements were done by
reverse transcriptase (RT) PCR on nasal, throat and rectal swabs,
endotracheal aspirates, pleural fluid and plasma.[18] The lower
limit of viral load detection is 1000 cDNA/ml. All respiratory
specimens were inoculated onto Madin Darby Canine Kidney
cells for influenza virus isolation. In vitro susceptibility of virus
isolates to OC were tested by a chemiluminiscent neuraminidase
inhibition assay (NA-Star, Applied Biosystems).
All patients were prescribed oseltamivir (TamifluH, Roche, Basel,
Switzerland) 150 mg bid (double dose)610 days for presumptive
H5N1; they were dosed 12 hourly at 3 pm and 3 am. When the
patients were ventilated, the powder in the capsule was dissolved in
20 mls of water, injected down the NG tube, followed by a 10 ml
sterile water flush. Oseltamivir solution is not available in our
hospital.Enteralfeeding(EnsureGoldH 250 mls3 hourly) wasgiven
daily from 6 am to 9 pm. All patients underwent CVVH (AN69
haemofilter, Rospal, France) at 45 mls/kg/hour in accordance with
local practice.Supportive treatment was given as clinically indicated
e.g. CVP guided intravenous fluids, cardiovascular support with
adrenaline, noradrenaline, dobuatamine, dopamine, chest drain for
pneumomediastnum and pneumothorax.
For PK measurements (predose, 05 h, 1 h, 1.5 h, 2 h, 5 h, 7 h,
9 h, 11 h, 12 h post dose), 2 ml of whole blood were collected into
fluoride-oxalate tubes [19,20] via a venous catheter (Patient A) or
the arterial and venous limbs of the haemofilter (only Patients B &
C were sampled on haemfiltration) $48 hours after starting
oseltamivir when all patients were receiving NG oseltamivir. The
ultrafiltrate (haemofilter exit port) was collected from Patient B.
Plasma was separated by centrifuging at 2000 g for 4 minutes and
stored at 280uC until analysed by using: (i) mixed mode (MPC-
SD, 3 M Empore Bracknell, UK) solid phase extraction and
hydrophilic interaction liquid chromatography mass spectrometry
(HILIC-LC-MS/MS), (ii) an API 5000 triple quadrupole mass
spectrometer (Applied Biosystems/MDS SCIEX, Foster City,
USA) equipped with a TurboV
TM ionisation source interface in
positive ion mode, (iii) an Agilent 1200 liquid chromatographic-
system (Agilent technologies, Santa Clara, USA) and (iv) Analyst
1.4 (Applied Biosystems/MDS SCIEX, Foster City, USA).[21]
The coefficients of variation (CV%) were 5.1%, 2.6% and 4.6% at
3 ng/mL, 20 ng/mL and 150 ng/mL, respectively, for oseltamivir
and 3.7%, 3.4% and 4.0% at 30 ng/mL, 400 ng/mL and
4000 ng/mL, respectively, for OC.
The OP and OC steady state area under the curve values over
12 hours (AUC0–12) were calculated using the trapezoidal rule
(Stata version 9) and clearances calculated as dose/AUC0-t,
(t=dosing interval). Estimated clearance is the apparent clearance
CL/f where f is the fraction of osetlamivir absorbed and converted
to OC. The haemofilter clearance (ml/min) of OC over the
12 hours dosing period was calculated using the formula UV/P
(U=ultrafiltrate concentration, ultrafiltrate volume, P=plasma
concentration).
Results
All patients were severely ill requiring mechanical ventilation
and treatment with inotropes/vasopressors within 24 hours of
ICU admission (Table 1). Patient C was in renal failure. The
CVVH ultrafiltration rates (L/h) and their approximate, equiva-
lent GFRs (ml/min) were 2.75 L/h [45.8 ml/min (patient A)],
2.2 L/h [36.7 ml/min (patient B)] and 2 L/h [33.3 ml/min
(patient C)]. All patients received intravenous antibiotics for
possible bacterial pneumonia and intravenous hydrocortisone
(300 mg daily). Patients A and C developed pneumomediastina
and bilateral and unilateral pneumothoraces, respectively, while
ventilated.
Patients B and C died of progressive respiratory failure 10 and
14 days after illness onset, respectively. Their antemortem chest X
rays had worsened since admission and showed progression from
unilateral to bilateral consolidation (A) and progressive bilateral
consolidation (C). Patient A was mechanically ventilated for 6 days
and survived. He complained of severe headache and had
persistent vomiting; consequently, his oseltamivir was stopped
after 8 days of treatment.
For viral specimen collection, Patient A was first sampled three
days after starting oseltamivir; only his tracheal aspirate was
positive and became negative after 5 days of oseltamivir treatment
(Figure 1). Patient B was sampled once, one day after starting
oseltamivir; her tracheal aspirate (1.14610
6 copy DNA copies/
ml), pleural fluid (2.66610
4), stool (3.2610
4) and plasma
(7.29610
3) were H5N1 positive. Patient C, sampled one day after
starting oseltamivir, cleared H3N2 virus from her nose swabs after
five days of treatment (Figure 2). Virus could not be isolated from
specimens of Patients A and C, possibly due to the effects of
oseltamivir. The in vitro IC50 of the isolate from Patient B (tracheal
aspirate) was 2.5 nM (0.69 ng) per mL.
Trough OC concentrations varied markedly: 376 (A), 575 (B)
and 2730 (C) ng/ml and were consistent with the steady state
Oseltamivir in Severe Flu
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These OC concentrations were 545 and 833 fold higher than the
IC50 value from the H5N1 virus isolated from Patient B and 3042
fold higher than the reported mean IC50s for H3N2 viruses (up to
0.9 ng/ml). The mean OC sieving coefficients were 1.055 (Patient
B) and 1.1 (Patient C). Oseltamivir and OC haemofilter
‘excretions’ were 1.4 and 25 mg over 12 hours for haemofilter
clearances of 25.19 and 41.46 ml/min, respectively.
Discussion
This study has shown that in ventilated patients with severe
influenza, NG administered, double dose oseltamivir was absorbed
and converted extensively to oseltamivir carboxylate. The OC
trough and peak concentrations were higher those reported in
healthy volunteers and were many fold higher than the reported
H5N1 and H3N2 IC50s. However, two patients died despite these
good PK parameters.
The current WHO guidelines suggest clinicians should consider
a double dose oseltamivir in severely ill patients because of the
uncertainty of oseltamivir absorption and the high disease
mortality. At the time of the study, there were no recommenda-
tions for patients on any form of renal replacement therapy from
the WHO or the manufacturer but there were PK data for patients
on chronic haemfiltration and CAPD[13] that have now been
incorporated in the manufacturer’s product information sheet. We
treated our patients presumptively with double dose oseltamivir,
including Patient C with the low creatinine clearance, because we
suspected they had H5N1, standard dose oseltamivir for H5N1 is
associated with a poor outcome in Viet Nam, and elsewhere, and
to guard against the unknown loss of OC through the haemofilter.
In the event, all patients had OC concentrations and AUC0–12
values that were 1.3 to 9 and 1.2 to 7 times higher than reported in
mild influenza/healthy volunteers, respectively, and are probably
related to the impaired renal function in our patients. At the
ultrafiltration rate used, the OC haemofilter loss was small, 25 mg
Table 1. Patients’ clinical, pharmacokinetic and virological features.
Patients A: Male, age 30 H5N1 B: Pregnant female, age 22 H5N1 C: Female, age 76 H3N2
Duration of illness in days pre ICU 8 6 7
Poultry exposure Y N N
Fever Y Y Y
Cough & shortness of breath Y Y Y
Vomiting Y N N
Diarrhoea N Y N
Weight kg 61 47.5 46
Temperature uC 40.1 38.2 39
Hb g/dL 15.5 10.3 8.3
Total white cell (lymphocyte) count /mL 5,600 5,400 16,800
Absolute lymphocyte count /mL 400 300 1680
Platelet count /mL 87,000 119,000 125,000
Serum Creatinine mmol/L 128 73 499
Creatinine clearance mls/min* 66 82 6
FI02, pH, PO2, PCO2, HCO3
2" 40%, 7.5, 34.9, 40.4, 30.9 32% 7.45, 42.7, 28.6, 19.8 50%, 7.43, 33.3, 28, 19
Day of ICU admission D0 D0 D0
CVVH started (start-stop Day) D4 to 7 D1 to 4 D1 to 8
Oseltamivir started (ICU Day) D0 D1 D2
Oseltamivir started from day of illness onset 8 7 9
Viral load cDNA copies/ml (Day measured) 3.12610
5 (D3) 1.14610
5 (D2) 2.79610
4 (D3)
PK sampling D8 D3 D5
Cmin OC ng/ml# 376 575 2730
Cmin OP ng/ml# 5.49 37.4 24.4
Cmax OC ng/ml 591 1210 1270
Cmax OP ng/ml 122 156 28.7
OC AUC0–12 ng.h/ml 5,932 10,951 34,670
OP AUC0–12 ng.h/ml 395 1059 628
OC oral clearance L/h 27.8 15.1 4.7
OP oral clearance L/h 380 141.5 238.7
Outcome (Day of death) Survived Died (D4) Died (D8)
*Cockroft Gault formula.
"Arterial blood gas prior to ventilation, mmHg: PO2,P C O 2, mmol/L:HCO3
2.
#OP=oseltamivir phosphate, OC=oseltamivir carboxylate.
doi:10.1371/journal.pone.0003410.t001
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does not warrant a compensatory dose increase. The H5N1 viral
loads in our patients were consistent with those (log10 cDNA 4.3–
8.2) from another Vietnamese series.[5]
The surviving patient started oseltamivir eight days into his
illness. His viral clearance time of 5 days post treatment is similar
to earlier observations.[5] When off the ventilator, he complained
of severe headache and vomiting so oseltamivir was stopped, with
good effect, after 8 days, two days short of the recommended
extended dose of 10 days. We believe these symptoms were
oseltamivir related which suggests his OC concentrations were
high and not well tolerated.
The pregnant patient had plasma OC concentrations over the
12 hours, exceeding ,833 fold the IC50 of her infecting H5N1
virus. Her calculated CCRCl (82 mls/min) is probably overesti-
mated given the dilutional effect of pregnancy. She had two poor
prognostic factors: she was treated late, 7 days after illness onset,
and had disseminated disease.[2,22] Despite the susceptibility of
Figure 1. Viral clearance in patients A. Day 0 is the day of illness onset.
doi:10.1371/journal.pone.0003410.g001
Figure 2. Viral clearance in patient C. Day 0 is the day of illness onset.
doi:10.1371/journal.pone.0003410.g002
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sequential viral load data preclude a conclusion regarding the
antiviral efficacy of oseltamivir.
The elderly female had the highest AUC0–12 and OC
concentrations. Her trough OC concentration was ,3000 to
6000 fold higher than the reported mean IC50 values (0.46 and
0.9 ng) for wild type H3N2 isolates but only ,2 to 60 fold higher
than the mean IC50 values (1076 ng, 43.6 ng) for some mutant
H1N1 and H3N2 viruses.[23,24] Although she cleared her virus
after 5 days of treatment, she died of respiratory failure. Her
CVVH GFR of ,33 ml/min was slightly above the 30 ml/min
cut off for halving the oseltamivir dose, justifying our initial
decision to give her double dose oseltamivir. Her OC Cmin is 2.7
fold higher than the mean Cmin (1000 ng/ml) and slightly higher
than the mean Cmax (2458 ng/ml) achieved after 500 mg bd of
oseltamivir.[12] Given these high OC concentrations, and our
knowledge that CVVH at the rate we used results in a small loss of
OC via the filter, we could have given her standard dose
oseltamivir and still seen viral clearance.
There were limitations to our study. Viral sampling was
incomplete and the plasma PK data were only collected once
over 12 hours. We did not measure OC from the lungs, the main
site of the pathology. Such data are needed to define more
precisely the PK PD relationships in severe influenza and to
determine a therapeutic range for patients with H5N1.
However, our data remove some of the uncertainty regarding
nasogastrically administered oseltamivir. 150 mg bid of oseltamivir
was tolerated, absorbed, and provided adequate plasma concen-
trations to arrest viral replication in ventilated, severely ill
influenza patients on 45 ml/kg/h of CVVH. Nevertheless, two
patients died. This may be due to late treatment and advanced
disease at presentation when viral or immunologically mediated
tissue pathology might be irreversible. Whether higher oseltamivir
dosages, the use of antiviral combinations or adjunctive treatment
might improve the outcome in patients with H5N1 influenza or
other forms of severe influenza requires further research.
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